ADMA Biologics Provides Regulatory Update for BIVIGAM

11:59 EDT 11 Oct 2018 | Investing News Network

ADMA Biologics (NASDAQ:ADMA) a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, announces that it has received a formal communication from the U.S. Food and Drug Administration stating that the FDA considers the Company’s … Continued

The post ADMA Biologics Provides Regulatory Update for BIVIGAM appeared first on Investing News Network.

Original Article: ADMA Biologics Provides Regulatory Update for BIVIGAM


More From BioPortfolio on "ADMA Biologics Provides Regulatory Update for BIVIGAM"

Quick Search


Relevant Topics

The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...